Pomalid Capsules
Pomalid (Pomalidomide 2/4 mg) — Natco third-generation IMiD for relapsed/refractory multiple myeloma after lenalidomide and bortezomib failure.
✓ Medicinsk gennemgået af Morgan Ellis — Apoteksforsker · 8 års erfaring · Sidst gennemgået: maj 2026
Hurtigt svar
Pomalid Capsules — Pomalidomide 2/4 mg (Natco Pharma). Third-generation IMiD for relapsed/refractory multiple myeloma after lenalidomide and bortezomib failure. Used in combination with low-dose dexamethasone or other anti-myeloma agents.
Hvad du får med MedsBase:
- WHO-GMP certificeret producent
- Diskret kuvertemballage uden mærkning
- Levering til hele verden
- Bedømt af 1.400+ kunder (læs anmeldelser)
📦 Genforsendelsesgaranti: hvis din ordre ikke er ankommet inden for 20 hverdage efter afsendelse, genforsender vi den uden ekstra omkostninger. Læs politikken.
Hvorfor bestille fra MedsBase
Pomalid Capsules ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
All IMiDs are severely teratogenic (thalidomide most notoriously — phocomelia). Mandatory pregnancy-prevention programme (REMS/iCare equivalent): pregnancy testing before, during, and after; two effective contraceptive methods; counselling for both partners; no blood donation during therapy or for 4 weeks after. Even one dose during pregnancy can cause severe malformations.
IMiDs carry significantly elevated risk of deep vein thrombosis and pulmonary embolism, especially in combination with corticosteroids or doxorubicin. Mandatory thromboprophylaxis: low-dose aspirin (low-risk), or LMWH/warfarin/DOAC (higher-risk patients). Specialist-determined.
All IMiDs cause myelosuppression — neutropenia, thrombocytopenia, anaemia. Weekly FBC during initiation; monthly maintenance. Renal dose adjustment (lenalidomide especially — significant renal accumulation).
Ofte stillede spørgsmål
When is this used?
Third-generation IMiD for relapsed/refractory multiple myeloma after lenalidomide and bortezomib failure. Used in combination with low-dose dexamethasone or other anti-myeloma agents.
How is it taken?
Once daily, typically in cycles (e.g., 21 days on, 7 days off for lenalidomide). Specific dose and schedule are myeloma-protocol-specific (Rd, RVd, KRd, etc.). Specialist-determined by tumour response and tolerability.
Pregnancy prevention?
Mandatory programme: monthly pregnancy tests, two effective contraceptive methods, partner contraception, counselling. Even one dose during pregnancy causes severe malformations. No blood donation during therapy or for 4 weeks after stopping.
Common side effects?
IMiD class: VTE, fatigue, rash, GI (constipation, diarrhoea), myelosuppression. Lenalidomide: less neuropathy than thalidomide. Pomalidomide: often better tolerated than thalidomide; renal-friendly. Thalidomide: peripheral neuropathy, sedation.
Lægemiddelinteraktioner?
Anticoagulants — adjust based on VTE prophylaxis strategy. Digoxin levels may rise. Erythropoietin agents + IMiD — increased thrombosis risk; use only with mandatory thromboprophylaxis.
Renal monitoring?
Lenalidomide: dose-adjust by CrCl (significant renal accumulation). Pomalidomide: less renal effect but still monitor. Thalidomide: renally cleared metabolite — monitor renal function.
Hvad hvis jeg glemmer en dosis?
Take when you remember if <12 hours late; otherwise skip and resume — do not double up. Notify oncology team if multiple doses missed.
Vaccination?
Inactivated vaccines OK; live vaccines contraindicated during IMiD therapy. Optimise vaccinations before starting if possible.
Long-term complications?
IMiD therapy: secondary primary malignancies (especially with extended use), cumulative VTE risk, neuropathy (thalidomide especially).
When is treatment stopped?
Specialist-determined: response duration, toxicity, planned treatment break, transition to maintenance therapy. IMiD maintenance therapy is now standard in myeloma — typically lenalidomide post-autologous stem cell transplant continued for 2-3 years or until intolerance.
Other Cancer Medications
- Xeloda — capecitabine 500 mg — oral 5-FU prodrug for breast/colorectal/gastric cancers
- Altraz — anastrozole 1 mg — aromatase inhibitor for post-menopausal breast cancer
- Xbira — abiraterone 250 mg — CYP17 inhibitor for metastatic prostate cancer
- Zoldria — zoledronic acid IV — for bone metastases and hypercalcaemia
- Actorise — darbepoetin alfa — for chemotherapy-induced anaemia
More options in Anti Cancer Medication
Rangeret efter seneste MedsBase ordrevolumen — hvad andre kunder i denne kategori vælger.
| Styrke | 2 mg, 4 mg |
|---|---|
| Antal | 21 Capsule/s, 42 Capsule/s, 63 Capsule/s |
| Farmaceutisk form | Kapsel(er) |
| Producent | Natco Pharma |
| Behandling | Multiple myeloma |
| Generisk mærke | Pomalidomide |
Pomalid Capsules
Spørgsmål & svar
Pomalid Capsules
Relaterede produkter
Anmeldelser
Der er ingen anmeldelser endnu